Compounds > rosiglitazone
Page last updated: 2024-08-25

rosiglitazone and Ischemia

rosiglitazone has been researched along with Ischemia in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's4 (57.14)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bartelik, A; Derlacz, R; Dulak, J; Grochot-Przeczek, A; Horrevoets, AJ; Jozkowicz, A; Kotlinowski, J; Kozakowska, M; Nagy, L; Pap, A; Pilecki, B; Skrzypek, K; Taha, H1
Higuchi, A; Ohashi, K; Ouchi, N; Shibata, R; Sono-Romanelli, S; Walsh, K1
Boerman, OC; Meijer, P; Oyen, WJ; Rennings, AJ; Rongen, GA; Smits, P; Tack, CJ; van Uden, DJ1
Greyson, CR; Lu, L; Reiter, MJ; Sarraf, M; Schwartz, GG; Ye, S1
Blanchard, J; Eismann, T; Galloway, E; Huber, N; Kuboki, S; Lentsch, AB; Pritts, TA; Schuster, R; Shin, T1
Diamond, RH; Forman, LM; Simmons, DA1
Boscia, J; Everitt, D; Freid, J1

Trials

1 trial(s) available for rosiglitazone and Ischemia

ArticleYear
Rosiglitazone reduces ischaemia-reperfusion injury in patients with the metabolic syndrome.
    European heart journal, 2010, Volume: 31, Issue:8

    Topics: Double-Blind Method; Forearm; Humans; Insulin Resistance; Ischemia; Metabolic Syndrome; Muscle, Skeletal; Radionuclide Imaging; Reperfusion Injury; Rosiglitazone; Thiazolidinediones; Vasodilator Agents

2010

Other Studies

6 other study(ies) available for rosiglitazone and Ischemia

ArticleYear
PPARĪ³ activation but not PPARĪ³ haplodeficiency affects proangiogenic potential of endothelial cells and bone marrow-derived progenitors.
    Cardiovascular diabetology, 2014, Nov-01, Volume: 13

    Topics: Animals; Bone Marrow; Bone Marrow Cells; Cells, Cultured; Endothelial Cells; Hypoglycemic Agents; Ischemia; Mice, Inbred C57BL; Neovascularization, Physiologic; PPAR gamma; Rosiglitazone; Stem Cells; Thiazolidinediones; Wound Healing

2014
Thiazolidinediones reduce pathological neovascularization in ischemic retina via an adiponectin-dependent mechanism.
    Arteriosclerosis, thrombosis, and vascular biology, 2010, Volume: 30, Issue:1

    Topics: Adiponectin; AMP-Activated Protein Kinases; Animals; Diabetic Retinopathy; Hypoglycemic Agents; Ischemia; Mice; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Pioglitazone; Retinal Vessels; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha

2010
Thiazolidinedione drugs promote onset, alter characteristics, and increase mortality of ischemic ventricular fibrillation in pigs.
    Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:3

    Topics: Animals; Anti-Arrhythmia Agents; Coronary Vessels; Death, Sudden, Cardiac; Decanoic Acids; Female; Glyburide; Hydroxy Acids; Hypoglycemic Agents; Ischemia; Ischemic Preconditioning, Myocardial; Male; Pioglitazone; Potassium Channel Blockers; Rosiglitazone; Swine; Thiazolidinediones; Ventricular Fibrillation

2012
Activation of peroxisome proliferator-activated receptor-gamma during hepatic ischemia is age-dependent.
    The Journal of surgical research, 2008, Jun-15, Volume: 147, Issue:2

    Topics: Age Factors; Animals; Autophagy; Hypoglycemic Agents; Ischemia; Ligands; Liver; Male; Mice; Mice, Inbred C57BL; PPAR gamma; Rosiglitazone; Thiazolidinediones

2008
Hepatic failure in a patient taking rosiglitazone.
    Annals of internal medicine, 2000, Jan-18, Volume: 132, Issue:2

    Topics: Aged; Combined Modality Therapy; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Ischemia; Liver; Liver Failure; Male; Monitoring, Physiologic; Pravastatin; Rosiglitazone; Thiazoles; Thiazolidinediones; Verapamil

2000
Rosiglitazone and hepatic failure.
    Annals of internal medicine, 2000, Jan-18, Volume: 132, Issue:2

    Topics: Coronary Disease; Humans; Hypoglycemic Agents; Ischemia; Liver; Liver Failure; Rosiglitazone; Thiazoles; Thiazolidinediones

2000